Evaluation of Anti-Cancer Oncology Medicines Pharmaceutical Companies Under Chain of Sustainable Procurement

Evaluation of Anti-Cancer Oncology Medicines Pharmaceutical Companies Under Chain of Sustainable Procurement

Anoop Kumar Sahu (Department of Mechanical Engg, Madanapalle Institute of Technology and Science, Andhra Pradesh, India)
DOI: 10.4018/IJSESD.2019070106

Abstract

Cancer is awful disease, which makes panicle network in the body system of patients. Cancer is characterized by abnormal and uncontrolled cell growth, which results in the formation of lumps or masses in body known as tumor. There are more than 100 types of cancers and each is classified according to the cell capacity and size. Globally, cancer is accepted as the second leading cause of death. As per a WHO report, cancer is responsible for 8.8 million deaths in 2015. Anti-cancer drugs or oncology medicines are employed in taking the care of different patients. At the present time, many pharmaceutical companies are active in producing oncology medicines. It is probed that by pharmaceutical scientists how cancer treatments under the scheduled time can save life of patients and a delay in treating cancer patients may have unseemly effects on the life of patients. The presented research focuses on two cases. The first was conducted at Jabalpur Hospital & Research Centre (JHRC), where a structure/model related to A-CMsP company is built for assessing the performance under chain of sustainable procurement criteria. The second research focuses on the benchmarking of two A-CMsP companies. A multi objective optimization approach is implemented, accompanied with vague modeling for computing the overall performance index of oncology medicines.
Article Preview
Top

1. Introduction And State Of Arts

Cancer is usually classified according to the tissue from which the cancerous cells originate. An authoritative diagnosis usually requires the histological examination of a tissue biopsy specimen by a pathologist, the initial indication of malignancy is considered as stage of cancer. Cancer is so serious disease that it can initiate from anywhere in the human body on account of trillions of cells. A cell becomes cancerous due to disruption in the cell DNA, changing the instructional system that supervises the life cycle of cells. Apart from this, many cancerous parameters in relational to everyday life of a person causes the disruption of life cycle of cells, result in the propagation of cancer in human being. The most usual cancerous parameters are genetic predisposition, estrogen exposure, ionizing radiation, ultraviolet B (UVB), carcinogenic chemicals, tobacco, smoking, alcohol, carcinogenic foods, unhealthy diet, antioxidants etc. Globally the most common cancer cases occurring in 2016 were bladder cancers, breast cancers, lung and bronchus cancers, colon, prostate cancers, leukemia, endometrial cancers, and pancreatic cancers, rectum cancers, non-Hodgkin lymphoma, thyroid cancers, kidney and renal, pelvic cancers. Recently, the National Cancer Institute (NSI) investigated the causes of USA cancer’s patients of 2010-2012 and found that approximately 39.6% of men and women are diagnosed with cancers during 2010-2012. NSI proposed the cancer’s patient report of 2010, USA, the 15,780 children and adolescents ages from 0 to 20 are diagnosed with cancer, while 1,961 are died. In 2016, NSI estimated 1,686, 211 cases of cancer, are diagnosed in the USA and 595,690 peoples are died. Anticancer drugs or Antineoplastics, are used in order to make the humans body enable to fight against cancer propagations cells.

Anti-cancer drugs are used to obstruct the growth of cancerous cells and enhance the performance of non-cancerous cells. Several anti-cancer drugs depend on the participation and involvement in propagations of cancerous cells. Many anti-cancer drugs associated with category of oncology medicines i.e. afinitor, netupitant and palonosetron hydrochloride, aldara, aldesleukin, alectinib, cabometyx, keytruda, lartruvo, lenvima, opdivo, opdivo, rubraca, sustol, etc., are used to provide the treatment against lung and other cancers Milken and Avalere (2016), Schwartzberg et al. (2016).

It is investigated that many people’s die in each year in cancer treatment hospital due to stoppage, holdup, impediment and delay in providing the treatment against lung and other cancer, happens due to low grads service and non-schedule delivery of oncology medicines to cancer treatment hospitals. In USA (2016), NSI estimated 1687 lung cancer patients out of 1,686, 211 and 168 lung cancer patients have died due to late supply of anti-cancer medicines to those hospitals in USA. The authors organized relevant literature review to construct the anti-cancer oncology medicines pharmaceutical companies’ appraisement hierarchical appraisement model and techniques for measuring the performance of anti-cancer oncology medicines vendors pharmaceutical companies (Chandra et al. 2016, Schnipper et al. 2016, National Comprehensive Cancer Network 2016, Milken and Avalere 2016). Most of the medicines purchasers use compound supply chains networks to maintain the stock of several medicines is called as pharma supply chain. The pharma supply chain of medicine supplier must be assessed in order to meet the medicine stock under schedule time, indirectly provides timely treatment to cancer’s patients and eliminate the cases of death (due to non-availability of medicines on schedule time). The pharma supply chain evaluation helps the medicine procurers to select the best Anti-Cancer Oncology Medicines Pharmaceutical Companies. The pharma supply chain assists the many retailers and medicine procurer to make right decision. But, many researches are conducted in the field of pharma supply chain under objective data consideration Baporikar (2017), Juliani et al, (2017), Ocampo and & Clark (2017), Rahmayanti & Ananda (2017). A few research documents are found in the area of subjective assessment of pharma supply chain. To conduct the further research work successfully, the authors decided to conduct literature survey in pharma supply chain.

Complete Article List

Search this Journal:
Reset
Open Access Articles
Volume 11: 4 Issues (2020): 2 Released, 2 Forthcoming
Volume 10: 4 Issues (2019)
Volume 9: 4 Issues (2018)
Volume 8: 4 Issues (2017)
Volume 7: 4 Issues (2016)
Volume 6: 4 Issues (2015)
Volume 5: 4 Issues (2014)
Volume 4: 4 Issues (2013)
Volume 3: 4 Issues (2012)
Volume 2: 4 Issues (2011)
Volume 1: 4 Issues (2010)
View Complete Journal Contents Listing